Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.64 |
| ▸ | BRD4 | O60885 | 16/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flosulide SCHEMBL195509 | 0.78 | PTGS2 (1.00) | PTGS2BRD4PTGS1 | |
| Flosulide SCHEMBL29454969 | 0.78 | PTGS2 (1.00) | PTGS2BRD4PTGS1 | |
| Flosulide SCHEMBL29383035 | 0.78 | PTGS2 (1.00) | PTGS2BRD4PTGS1 | |
| SCHEMBL16047515 | 0.78 | PTGS2 (0.62) | PTGS2BRD4EP300PTGS1MAPK8 | |
| SCHEMBL4405855 | 0.77 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL16045908 | 0.77 | PTGS2 (0.61) | PTGS2BRD4EP300PTGS1MAPK8 | |
| SCHEMBL10955991 | 0.76 | PTGS2 (0.70) | PTGS2BRD4PTGS1 | |
| SCHEMBL8524487 | 0.76 | PTGS2 (0.59) | PTGS2BRD4EP300PTGS1MAPK8 | |
| SCHEMBL10416533 | 0.75 | PTGS2 (0.59) | PTGS2BRD4EP300PTGS1MAPK8 | |
| SCHEMBL9807189 | 0.75 | PTGS2 (0.64) | PTGS2BRD4EP300PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | STEPHENSON DIANE T | 2007-06-28 | — | — | US | disclosed |
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | STEPHENSON DIANE T | 2007-06-28 | — | — | US | disclosed |
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2006-06-22 | — | — | US | disclosed |
| US-20050130971-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION | 2005-06-16 | — | — | US | disclosed |
| WO-2005046615-A2 | COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM MEDIATED DISORDERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050065154-A1 | Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents | PHARMACIA CORPORATION | 2005-03-24 | — | — | US | disclosed |
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-10 | — | — | US | disclosed |
| WO-2005018563-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018569-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005009354-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN IKK INHIBITOR FOR THE TREATMENT OF ISCHEMIC-MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005007156-A1 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007106-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004103286-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CHOLIMERGIC AGENT | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004093814-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM CHANNEL BLOCKER | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093816-A2 | COMPOSITIONS COMPRISING A SELECTIVE COX-2 INHIBITOR AND A CALCIUM MODULATING AGENT | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093811-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM ION CHANNEL BLOCKER FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093813-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CALCIUM MODULATING AGENT FOR THE TREATMENT OF PAIN, INFLAMMATION OR INFLAMMATION MEDIATED DISORDERS | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004060366-A1 | A METHOD FOR THE TREATMENT, PREVENTION, OR INHIBITION OF A CNS DISORDER AND/OR PAIN AND INFLAMMATION USING A COMBINATION OF DULOXETINE, VENLAFAXINE OR ATOMOXETINE AND A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND COMPOSITIONS THEREOF | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | TXNRD2, PRDX5, PTGS2 | PTGS2 3/4885BRD4 3602/4885EP300 3208/4885 |
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885BRD4 1438/4885EP300 3419/4885 |
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885BRD4 4194/4885EP300 2639/4885 |
| US-20050130971-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PDE2A, PDE3B, PDE3A | PTGS2 8/4885BRD4 3879/4885EP300 4204/4885 |
| US-20050065154-A1 | Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885BRD4 769/4885EP300 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.